A Real-World Study: Effect of the Third-Line Therapy of Fruquintinib or Regorafenib Therapy Versus Rechallenge Chemotherapy in Metastatic Colorectal Cancer
{{output}}
Aim: Third-line treatment options for metastatic colorectal cancer (mCRC) remain limited. Chemotherapy rechallenge has shown efficacy in this setting, but direct comparisons with tyrosine kinase inhibitors (TKIs) are lacking. Thi... ...
